Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome

Gut

Volumn 60, Issue 7, 2011, Pages 902-914

  Jeppesen, Palle Bekker ^a   Gilroy, R ^b   Pertkiewicz, M ^c   Allard, J P ^d   Messing, B ^e   O'Keefe, S J ^f  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d UNIVERSITY OF TORONTO   (Canada)

^e BEAUJON HOSPITAL   (France)

^f UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFUSION FLUID; PLACEBO; TEDUGLUTIDE;

ABDOMINAL PAIN; ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; ASTHENIA; BODY MASS; COMA; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; ENTEROPATHY; FEMALE; FLUID INTAKE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEMORRHOID HEMORRHAGE; HUMAN; HYPERSOMNIA; INFECTION; INTESTINE FLUID; MAJOR CLINICAL STUDY; MALE; NAUSEA; PANCREATITIS; PARENTERAL NUTRITION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEPSIS; SHORT BOWEL SYNDROME; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ALGORITHMS; BODY COMPOSITION; BODY WEIGHT; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUID THERAPY; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; PARENTERAL NUTRITION; PEPTIDES; SHORT BOWEL SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79958187560     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.218271     Document Type: Article

References (28)

1. Messing B, Pigot F, Rongier M, et al. Intestinal absorption of free oral hyperalimentation in the very short bowel syndrome. Gastroenterology 1991;100:1502-8.
2. Jeppesen PB, Mortensen PB. Intestinal failure defined by measurements of intestinal energy and wet weight absorption. Gut 2000;46:701-6. (Pubitemid 30305789)
3. Fleming CR, Remington M. Intestinal failure. In: Hill GL, ed. Nutrition and the Surgical Patient. New York: Churchill Livingstone, 1981:219-35.
4. O'Keefe SJ, Buchman AL, Fishbein TM, et al. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol 2006;4:6-10. (Pubitemid 43129518)
5. Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology 2003;124:1111-34. (Pubitemid 36389810)
6. Nightingale JM, Lennard Jones JE. The short bowel syndrome: what's new and old? Dig Dis 1993;11:12-31.
7. Messing B, Crenn P, Beau P, et al. Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome. Gastroenterology 1999;117:1043-50. (Pubitemid 29512662)
8. Goulet O, Joly F, Corriol O, et al. Some new insights in intestinal failure-associated liver disease. Curr Opin Organ Transplant 2009;14:256-61.
9. Lauverjat M, Hadj AA, Vanhems P, et al. Chronic dehydration may impair renal function in patients with chronic intestinal failure on long-term parenteral nutrition. Clin Nutr 2006;25:75-81. (Pubitemid 43263530)
10. Jeppesen PB, Langholz E, Mortensen PB. Quality of life in patients receiving home parenteral nutrition. Gut 1999;44:844-52. (Pubitemid 29244222)
11. Baxter JP, Fayers PM, McKinlay AW. A review of the quality of life of adult patients treated with long-term parenteral nutrition. Clin Nutr 2006;25:543-53. (Pubitemid 44070594)
12. Drucker DJ, Erlich P, Asa SL, et al. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A 1996;93:7911-16.
13. Wojdemann M, Wettergren A, Hartmann B, et al. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 1998;33:828-32. (Pubitemid 28423636)
14. Wojdemann M, Wettergren A, Hartmann B, et al. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. J Clin Endocrinol Metab 1999;84:2513-17.
15. Bremholm L, Hornum M, Henriksen BM, et al. Glucagon-like peptide-2 increases mesenteric blood flow in humans. Scand J Gastroenterol 2009;44:314-19.
16. Cani PD, Possemiers S, Van de WT, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009;58:1091-103.
17. Brubaker PL, Izzo A, Hill M, et al. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol 1997;272(6 Pt 1): E1050-8.
18. Henriksen DB, Alexandersen P, Hartmann B, et al. Four-month treatment with GLP-2 significantly increases hip BMD A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 2009;45:833-42.
19. Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 2001;120:806-15. (Pubitemid 32193176)
20. Jeppesen PB, Lund P, Gottschalck IB, et al. Short bowel patients treated for two years with glucagon-like peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract 2009;2009:616054.
21. Jeppesen PB, Lund P, Gottschalck IB, et al. Short bowel patients treated for two years with glucagon-like peptide 2 (GLP-2): compliance, safety, and effects on quality of life. Gastroenterol Res Pract 2009;2009:425759.
22. Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005;54:1224-31. (Pubitemid 41192479)
23. Crenn P, Coudray-Lucas C, Thuillier F, et al. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. Gastroenterology 2000;119:1496-505. (Pubitemid 32198675)
24. Ware JE Jr, Sherbourne CD, The MOS. 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
25. Kind P. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, PA: Lippincott-Raven Press, 1996:191-201.
26. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804-10. (Pubitemid 19057603)
27. Caddy G, Johnston C, Ardill J, et al. Distribution of glucagon-like peptide-2 in normal colonic tissue. Scand J Gastroenterol 2003;38:798-9. (Pubitemid 36920504)
28. Jeppesen PB, Hartmann B, Thulesen J, et al. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut 2000;47:370-6.